TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16792792

Group type: EXPERIMENTAL
Intervention: Home-based, individually tailored physical rehabilitation programme (8-week duration, including graded, individualized endurance and strength training, three home visits, five follow-up phone calls, and a printed exercise manual)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Home-based, individually tailored physical rehabilitation programme
Number of subjects: 200
Study: 12762347

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone over 24 hours
Number of subjects: 26
Study: 11061530

Group type: EXPERIMENTAL
Intervention: Daily rGH injections (Group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Thrice weekly rGH injections (Group B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups after 6 months of therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups after 12 months of therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (34 healthy subjects)
Number of subjects: 34
Study: 8988215

Group type: EXPERIMENTAL
Intervention: iohexol (nonionic contrast medium)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 10
Study: 8598549

Group type: COMPARATOR
Intervention: RRR-alpha-tocopheryl acetate (TA) 0 mg/d
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (TA) 100 mg/d
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (TA) 200 mg/d
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopheryl acetate (TA) 400 mg/d
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fish oil supplement
Number of subjects: 48
Study: 2573364

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36) followed up by a nurse once a month and by a doctor every third month for 12 months.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (n = 42) with no intervention.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 36)
Number of subjects: 78
Study: 4555773

Group type: EXPERIMENTAL
Intervention: A2/England/1/1966 vaccine (300 CCA)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: A/equine 2/Miami/1963 vaccine (300 CCA)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 30399474

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 500

Group type: COMPARATOR
Intervention: TV-ICD
Number of subjects: 500
Study: 28450082

Group type: EXPERIMENTAL
Intervention: Children's book
Number of subjects: 282

Group type: COMPARATOR
Intervention: Brochures
Number of subjects: 282
Study: 26049123

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (60 mg/m²) and carboplatin (AUC 2.7) with prophylactic G-CSF (filgrastim) given on day 5 (and if needed on day 6)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Historical data without routine use of prophylactic G-CSF
Number of subjects: 108
Study: 23945031

Group type: EXPERIMENTAL
Intervention: Method A (measures both INR variability and control)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Low TIR (< 39%)
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Method B2 (measures variability only)
Number of subjects: 819
Study: 21691608

Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 25

Group type: COMPARATOR
Intervention: Resilient telescopic crowns
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 20001678

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-SMBG (control group)
Number of subjects: 0
Study: 16769471

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone treatment
Number of subjects: 9
Study: 12897375

Group type: EXPERIMENTAL
Intervention: Suppressed TSH levels (untreated)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal TSH
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Treated hyperthyroidism
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Subnormal but not suppressed TSH
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Euthyroid patients with positive thyroid antibody titers
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism
Number of subjects: 93
Study: 10976979

Group type: EXPERIMENTAL
Intervention: Echinacea Plus tea (5 to 6 cups per day for 5 days)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 9129557

Group type: EXPERIMENTAL
Intervention: Regular-strength grapefruit juice with 60 mg terfenadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice with 60 mg terfenadine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water with 60 mg terfenadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regular-strength grapefruit juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Double-strength grapefruit juice
Number of subjects: 12
Study: 8415264

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Tilade) in the form of metered dosimeter aerosol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2868573

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 60
Study: 29356576

Group type: EXPERIMENTAL
Intervention: 600 mg Alpha-Lipoic Acid (ALA) per day for 1 month before surgery and for 2 months afterward
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo per day for 1 month before surgery and for 2 months afterward
Number of subjects: 20
Study: 27863207

Group type: EXPERIMENTAL
Intervention: Morning combined strength and endurance training (mE + S)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Evening combined strength and endurance training (eE + S)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Morning combined strength and endurance training (mS + E)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Evening combined strength and endurance training (eS + E)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All groups (mE + S, mS + E, eE + S, eS + E)
Number of subjects: 42
Study: 24190902

Group type: EXPERIMENTAL
Intervention: Home blood pressure (HBP) monitoring alone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Combined clinic and ambulatory blood pressure (ABP) measurements
Number of subjects: 145
Study: 22267825

Group type: EXPERIMENTAL
Intervention: Patients with silent brain infarction (SBI)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Patients without silent brain infarction (SBI)
Number of subjects: 1014
Study: 20635452

Group type: EXPERIMENTAL
Intervention: 4.5 mm thin rod
Number of subjects: 49

Group type: COMPARATOR
Intervention: 5.5 mm thick rod
Number of subjects: 49
Study: 18687828

Group type: EXPERIMENTAL
Intervention: Two-strand repair
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Four-strand repair
Number of subjects: 29
Study: 15753789

Group type: EXPERIMENTAL
Intervention: Gated SPECT images
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected gated SPECT images
Number of subjects: 15
Study: 12501944

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural arthritis education programme
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard arthritis education programme (control group)
Number of subjects: 54
Study: 10622650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pegorgotein, 2,000 IU/kg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pegorgotein, 5,000 IU/kg
Number of subjects: 67
Study: 7724304

Group type: EXPERIMENTAL
Intervention: Amnioinfusion for oligohydramnios in labor
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 42
Study: 1828550

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 10 mg daily (days 12-25)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (identical to medroxyprogesterone acetate)
Number of subjects: 48
Study: 6313501

Group type: EXPERIMENTAL
Intervention: 15 g guar gum
Number of subjects: 10
Study: 31380663

Group type: EXPERIMENTAL
Intervention: Borrowers showing greater positive arousal (e.g., excitement) in profile photos
Number of subjects: 13500

Group type: EXPERIMENTAL
Intervention: Borrowers showing open 'excited' smiles
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Excited borrowers
Number of subjects: 13500
Study: 31094789

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 27
Study: 28415937

Group type: EXPERIMENTAL
Intervention: Heparin saline (50 IU/ml, 3 ml)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Normal saline (3 ml)
Number of subjects: 286
Study: 25733465

Group type: EXPERIMENTAL
Intervention: Child Food Insecurity (CFI)
Number of subjects: 3605
Study: 24390887

Group type: EXPERIMENTAL
Intervention: Enhanced feedback (weight, BMI, blood pressure, homeostatic insulin resistance, nuclear magnetic resonance lipoprotein profiles at 2, 4, 7, and 10 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited feedback (weight, BMI, and blood pressure at 4 and 10 months)
Number of subjects: 0
Study: 22848481

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 160
Study: 19276983

Group type: EXPERIMENTAL
Intervention: High dose of alcoholic red wine (8.1±0.9 dl)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dealcoholized red wine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognac (2.4±0.3 dl)
Number of subjects: 22
Study: 17445412

Group type: EXPERIMENTAL
Intervention: Intravenous Acehytisine Hydrochloride (AHH) 4 mg/kg, iv.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Propafenone (PRO) 1 mg/kg, iv.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intravenous Acehytisine Hydrochloride (AHH)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Propafenone (PRO)
Number of subjects: 201
Study: 15359921

Group type: EXPERIMENTAL
Intervention: Met-PET scan
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Histological examination
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Follow-up MR findings
Number of subjects: 11
Study: 11176735

Group type: COMPARATOR
Intervention: Sibutramine hydrochloride alone (drug-alone group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sibutramine plus group lifestyle modification (drug-plus-lifestyle group)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Sibutramine plus portion-controlled diet (combined treatment group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Drug-alone group
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Drug-plus-lifestyle and combined treatment groups
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study: 9608581

Group type: EXPERIMENTAL
Intervention: Yohimbine (α2 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8140046

Group type: EXPERIMENTAL
Intervention: Sandimmune (300 mg) under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sandimmune (300 mg) after a high-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral (180 mg) under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral (180 mg) after a high-fat meal
Number of subjects: 24
Study: 3132732

Group type: EXPERIMENTAL
Intervention: Helium ion radiation therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Split-course megavoltage photon irradiation
Number of subjects: 49
Study: 29761915

Group type: EXPERIMENTAL
Intervention: Teduglutide (TED) 0.05 mg/kg/day
Number of subjects: 14
Study: 28405683

Group type: EXPERIMENTAL
Intervention: Bladder intracavitary hyperthermic perfusion chemotherapy (BHPC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone
Number of subjects: 53
Study: 26244758

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 1408
Study: 24011094

Group type: EXPERIMENTAL
Intervention: Family cohesion and substance use
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Family support, care and connection; reducing substance use
Number of subjects: 179

Group type: COMPARATOR
Intervention: Family conflict, depressive symptoms, delinquency, school enrollment
Number of subjects: 179
Study: 20967571

Group type: EXPERIMENTAL
Intervention: Exercise support therapy (ST)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo therapy (PT)
Number of subjects: 29
Study: 18543585

Group type: EXPERIMENTAL
Intervention: Indirect measurement of blood loss calculation based on post-operative drop in haemoglobin (Hb) in pregnant women
Number of subjects: 66

Group type: COMPARATOR
Intervention: Indirect measurement of blood loss calculation based on post-operative drop in haemoglobin (Hb) in non-pregnant women
Number of subjects: 66
Study: 16498858

Group type: EXPERIMENTAL
Intervention: Topical cetirizine‐dinitrate (2.44 mg per nasal cavity) delivered via nasal spray device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline lavage before treatment)
Number of subjects: 0
Study: 15486848

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 224
Study: 10930904

Group type: EXPERIMENTAL
Intervention: RAC400 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 200 mg b.d.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RAC800 (rabeprazole 10 mg b.d., amoxycillin 750 mg b.d., clarithromycin 400 mg b.d.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RAC400
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RAC800
Number of subjects: 100
Study: 9032502

Group type: EXPERIMENTAL
Intervention: Individualized training (IT) at heart rate corresponding to gas exchange threshold (GET)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standardized training (ST) at heart rate corresponding to 50% of maximal heart rate reserve
Number of subjects: 24
Study: 8519379

Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled kallidin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled [desArg9]-bradykinin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled kallidin after bradykinin challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin after kallidin challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Repeated exposures with inhaled [desArg9]-bradykinin
Number of subjects: 10
Study: 2958234

Group type: EXPERIMENTAL
Intervention: Commercial cream for glass fibre itching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silicone spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emollient cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cream-ointment
Number of subjects: 0
Study: 29016734

Group type: COMPARATOR
Intervention: Intraoral and panoramic radiography (M1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cone Beam CT and panoramic radiography (M2)
Number of subjects: 112
Study: 26897130

Group type: EXPERIMENTAL
Intervention: Enhanced counseling session
Number of subjects: 561

Group type: COMPARATOR
Intervention: Standard of care counseling session
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Both enhanced and standard counseling sessions
Number of subjects: 561
Study: 25690407

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic treatment
Number of subjects: 70
Study: 24136138

Group type: EXPERIMENTAL
Intervention: Intensified training (n = 13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal training (n = 8)
Number of subjects: 21
Study: 20504977

Group type: EXPERIMENTAL
Intervention: Increased glycemic load test foods
Number of subjects: 15

Group type: COMPARATOR
Intervention: Decreased glycemic load test foods
Number of subjects: 15
Study: 18398365

Group type: EXPERIMENTAL
Intervention: Subthreshold infrared laser (810 nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional macular laser (fellow eye)
Number of subjects: 20
Study: 15717460

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with fentanyl 2.2 microg/ml
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bupivacaine 0.125%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 36
Study: 12707429

Group type: EXPERIMENTAL
Intervention: Pregabalin (600 mg/day for creatinine clearance > 60 mL/min or 300 mg/day for creatinine clearance 30 to 60 mL/min)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 10658522

Group type: EXPERIMENTAL
Intervention: Timing of mastectomy in the follicular phase
Number of subjects: 721

Group type: COMPARATOR
Intervention: Timing of mastectomy in the luteal phase
Number of subjects: 721
Study: 8665064

Group type: EXPERIMENTAL
Intervention: Rifampin, isoniazid, and pyrazinamide for two months, followed by rifampin and isoniazid for six months (n = 101)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for eight months (n = 90)
Number of subjects: 191
Study: 1987228

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide infusion (16 ng/kg per min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide infusion
Number of subjects: 8
Study: 6342165

Group type: EXPERIMENTAL
Intervention: SAC plus 1 g ascorbic acid (Redoxon) daily for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard anti‐asthma chemoprophylaxis (SAC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1 g intravenous injection)
Number of subjects: 16
Study: 30139712

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 16
Study: 29563289

Group type: EXPERIMENTAL
Intervention: Maraviroc monotherapy
Number of subjects: 20
Study: 26772807

Group type: EXPERIMENTAL
Intervention: Insulin analogues (AI) - insulin detemir and insulin aspart
Number of subjects: 109

Group type: COMPARATOR
Intervention: Human insulin (HI) - NPH-insulin and regular HI
Number of subjects: 109
Study: 24910870

Group type: EXPERIMENTAL
Intervention: Retinyl retinoate-loaded dissolving microneedle patches
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ascorbic acid-loaded dissolving microneedle patches
Number of subjects: 24
Study: 22834992

Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional thrice weekly hemodialysis
Number of subjects: 51
Study: 20218830

Group type: EXPERIMENTAL
Intervention: Guided use with worksheets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anatomy special study module (dissection of the digestive system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other students (not in the special study module)
Number of subjects: 0
Study: 17464379

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at levels of 0 cm H2O, 2 cm H2O, 4 cm H2O, 6 cm H2O, 8 cm H2O, and 10 cm H2O
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 11
Study: 16312171

Group type: EXPERIMENTAL
Intervention: 0.4% olopatadine nasal spray
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: 0.6% olopatadine nasal spray
Number of subjects: 677

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 677
Study: 12393661

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 186
Study: 10214857

Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplantation (APSCT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ABMT or APSCT
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 83
Study: 8657828

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol [Estraderm TTS (ETTS) 50 micrograms, applied twice weekly]
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 2229462

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 358427

Group type: EXPERIMENTAL
Intervention: Carbuterol (2.0 mg tablets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoterol (2.5 mg tablets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (1 mg tablets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbuterol (200 mg aerosol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 mg aerosol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexoprenaline (200 mg aerosol)
Number of subjects: 0
Study: 31851111

Group type: EXPERIMENTAL
Intervention: Adipose-Derived Cellular Bone Matrix (ACBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous Bone Graft
Number of subjects: 0
Study: 28838469

Group type: EXPERIMENTAL
Intervention: Alprazolam (double‐blinded, placebo‐controlled crossover)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Threat-induced anxiety
Number of subjects: 19
Study: 25668261

Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (37.5 mg of elemental iron) daily for 24 weeks (168 days)
Number of subjects: 215

Group type: COMPARATOR
Intervention: No iron supplementation
Number of subjects: 215
Study: 24170325

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22420121

Group type: EXPERIMENTAL
Intervention: Referential communication training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Communicative game (untrained group)
Number of subjects: 20
Study: 19414968

Group type: COMPARATOR
Intervention: Oral midazolam 0.6 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.6 mg/kg plus nitrous oxide-oxygen inhalation
Number of subjects: 30
Study: 17705833

Group type: EXPERIMENTAL
Intervention: Personal computer and fast Internet access at home (Intervention group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 123